Proteomic approaches in cancer risk and response assessment.
Proteomics is more than just a list-generating exercise where increases or decreases in protein expression are identified. Proteomic technologies will ultimately characterize information-flow through the protein circuitry that interconnects the extracellular microenvironment to the serum or plasma macroenvironment through intracellular signaling systems and their control of gene transcription. The nature of this information can be a cause or a consequence of disease processes and how patients respond to therapy. Analysis of human cancer as a model for how proteomics can have an impact at the bedside can take advantage of several promising new proteomic technologies. These technologies are being developed for early detection and risk assessment, therapeutic targeting and patient-tailored therapy.
Petricoin
Emanuel F
EF
FDA-NCI, Clinical Proteomics Program, Building 29A, Room 2D12, 8800 Rockville Pike, Bethesda, MD 20892, USA. petricoin@cber.fda.gov
Liotta
Lance A
LA
D014408:Biomarkers, Tumor; D020869:Gene Expression Profiling / Q000295:instrumentation / Q000379:methods; D006801:Humans; D025202:Molecular Diagnostic Techniques / Q000295:instrumentation / Q000379:methods; D009363:Neoplasm Proteins / Q000032:analysis / Q000378:metabolism; D009369:Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D040901:Proteomics; D018570:Risk Assessment; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins